Answers are grounded in this paper and cite their sources.
Our results suggest that both primary tumors and metastases of PDAC have highly fibrotic stroma. Thus, stromal targeting agents have the potential to benefit PDAC patients, even those with metastatic disease.
No takes yet. Share an insight, caveat, or question.
Whatcott et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: